Pazopanib altered the in vitro signaling of a brain metastatic derivative of MDA-MB-231 breast carcinoma cells, 231-BR, resulting in a reduction in the activity of the ERK pathway despite the presence of both Ras and B-Raf mutations. Here, BRAF is linked to breast carcinoma.